Shares of Lupin were trading in the green and 1% higher on 10 January after the company announced the launch of a cataract surgery pain reduction drug.

In its regulatory filing, the company said that it had launched Bromfenac Ophthalmic Solution, 0.07%, after it received approval from the USFDA (US Food and Drug Administration).

The company added that they are exclusive first-to-file for this product and are eligible for 180-day exclusivity.

Bromfenac Ophthalmic Solution, 0.07%, is a generic equivalent of Prolensa Ophthalmic Solution, 0.07%, that is made by Bausch & Lomb Inc. and is used in the treatment of postoperative inflammation and in the reduction of ocular pain in patients who have undergone cataract surgery.

Last week, the company received USFDA approval for its abbreviated new drug application for dapagliflozin and saxagliptin tablets.

In December 2023, the pharma company received an American regulator nod to market its generic loteprednol etabonate ophthalmic suspension for seasonal allergic conjunctivitis.

The shares touched a 52-week high of Rs 1,429.95 on 5 January 2024 and a 52-week low of Rs 628.10 on 31 March 2023.

At 10:30 am, Lupin’s shares were trading 0.21% higher at Rs 1,399.25 on NSE.